Asahi Kasei

Mangrove Lithium is a Vancouver-based company specializing in the innovative production of battery-grade lithium hydroxide and carbonate. The company has developed a modular and scalable refining technology that efficiently converts lithium chloride and lithium sulfate from various feedstocks. This versatile platform can be tailored to meet different production capacities and can be situated alongside upstream lithium producers or manufacturers of cathodes and cells. Additionally, Mangrove Lithium's technology is being commercialized for the conversion of waste brines into valuable chemicals and desalinated water, positioning the company as a key player in the sustainable lithium production landscape.

24M Technologies specializes in the development of innovative energy storage systems aimed at enhancing the operational reliability and efficiency of electric power systems for both grid and transportation applications. The company is known for its advanced lithium-ion batteries, which feature binder-free semisolid electrodes and unit cells. These designs not only improve battery performance but also streamline the recycling process by eliminating the need for traditional hydro or pyrometallurgical methods. Additionally, 24M facilitates the direct reuse of active materials within its manufacturing process, supporting sustainable end-of-life recycling practices. Through these innovations, 24M aims to provide clients with improved economic outcomes while contributing to more efficient energy storage solutions.

Calliditas Therapeutics AB, headquartered in Stockholm, Sweden, is a specialty pharmaceutical company dedicated to developing high-quality medicines for patients with significant unmet medical needs in niche indications. The company focuses on the development and commercialization of Nefecon (also known as TARPEYO), a unique formulation designed to treat IgA nephropathy (IgAN), an inflammatory renal disease. This patented, locally acting formulation combines a time lag effect with a concentrated release of budesonide within a designated target area. Calliditas is conducting a global Phase 3 study for Nefecon and aims to commercialize it in the United States.

Cyto-Facto is a biotechnology company specializing in the development and manufacturing of CAR-T cell therapies and mesenchymal stem cell products. It operates a research and development center dedicated to establishing quality standards for cell preparations used in gene and cell therapies. The company produces commercial CAR-T cell therapy products, including mesenchymal stem cells, and provides services such as management system development, sales support, and process development to help clients efficiently and reliably bring gene and cell therapies to patients.

Avation Medical, Inc. is a company focused on developing a non-invasive closed-loop neuromodulation system aimed at treating overactive bladder in a home setting. Incorporated in 2016 and based in Columbus, Ohio, Avation Medical is at the forefront of innovation in wearable nerve stimulation systems. The company emphasizes empowering patients to manage their therapies, facilitating a more personalized approach to care. By leveraging advanced technologies, Avation Medical seeks to transform the neuromodulation market, enhancing the quality of care for individuals with chronic conditions through patient-centric solutions.

Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

LeadSound Technology researches battery non-destructive testing and monitoring technology. Their lithium-ion batteries are the technologies for the development of emerging industries such as renewable energy, energy vehicles, and information technologies. Their exploration of the health status and failure mechanism of lithium-ion batteries is bottlenecks restricting the development of battery technology, and lithium-ion batteries.

Ionomr Innovations Inc. is a Canadian company specializing in the design, adaptation, and manufacture of advanced ion-exchange membranes and polymer technologies. Founded in 2013 and based in Vancouver, Ionomr is focused on providing solutions for clean technology applications, including water treatment, energy storage, and hydrogen production. Their Aemion membrane systems are notable for being alkaline-stable, highly durable, and versatile, enabling clients to improve performance while minimizing environmental impact. By replacing toxic fluorinated chemicals with eco-friendly hydrocarbon alternatives, Ionomr aims to reduce pollution and enhance the sustainability of electrochemical systems. The company also offers chemical engineering services, further supporting the integration of its innovative materials into various applications, contributing to the development of cleaner and more resilient energy solutions.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

Natural Fiber Welding, Inc., founded in 2015 and based in Peoria, Illinois, specializes in the manufacture and supply of sustainable fabrics and materials derived from natural fibers. The company has developed a circularity platform that produces high-performance, plastic-free materials from plants, which are applicable across various industries, including fashion, footwear, automotive, and upholstery. By integrating its innovative technology into existing supply chains, Natural Fiber Welding enables brands to design and scale environmentally friendly products, thereby promoting sustainability in material usage.

Castor Technologies, established in 2017 and based in Tel Aviv, Israel, specializes in developing 3D printing software. This software connects manufacturers with 3D printing capabilities, aiding them in evaluating how to integrate industrial 3D printing into their production processes. By offering a detailed technical and cost-saving analysis for an entire bill of materials, Castor empowers designers, new product introduction managers, and production engineers to make informed decisions when producing machine parts.

Curreio is a biotechnology company that develops a platform for drug discovery using structural analysis with cryo-electron microscopy. The platform enables observation of in vivo structures by freezing samples without staining, supporting the discovery and analysis of life-saving drugs through structural analysis–based approaches.

iVexSol Inc. is a biotechnology company based in Worcester, Massachusetts, specializing in the development of lentiviral vector (LVV) manufacturing technology. Established in 2018, the company addresses the critical shortage of LVVs, which serve as essential gene delivery vehicles in the production of cell and gene therapies (CGTs). iVexSol's innovative platform, known as Intelligent Vector Solutions, significantly enhances the scalability and cost-effectiveness of LVV production while reducing the complexity and development time associated with critical reagents. By employing banks of vector-producing cells, the technology allows for the generation of LVVs in higher quantities compared to traditional methods, thereby facilitating quicker scale-up and meeting global demand. This advancement not only shortens clinical development timelines but also aims to improve patient access to life-saving treatments for conditions such as later-stage cancers and various genetic disorders.

Multus is a London-based company established in 2019 that specializes in providing tailored growth media solutions for the cultivated meat industry. By utilizing a machine learning-based approach, Multus develops completely animal-free growth media designed specifically for the efficient growth of animal cells. This innovative technology enables cultivated meat companies to scale their production affordably and sustainably, allowing them to focus on creating delicious and environmentally friendly meat alternatives. Additionally, Multus optimizes a variety of growth factor proteins produced by genetically engineered microorganisms, thereby eliminating the reliance on traditional animal serum-based media. Through its efforts, Multus aims to address the diverse needs of various animal cell types and tissues, facilitating the growth of the cultivated meat sector while significantly reducing the environmental and economic impacts associated with conventional meat production.

Plant Prefab specializes in constructing custom single-family and multi-family homes using advanced prefabrication methods. Their proprietary Plant Building System employs digital modeling and modular components called Plant Panels and Plant Modules, allowing contractors and developers to complete projects 20-50% faster than traditional on-site construction. This system ensures superior quality control, design flexibility, and significant time, cost, and material efficiency. Committed to sustainability, Plant Prefab aims to build a better world by design, having achieved carbon-neutral operations since 2020 and being the first housing prefabricator to announce a net-zero goal.

Circularise is a provider of digital product passports and mass balance bookkeeping software, focusing on sustainability and supply chain transparency. The company’s software aids suppliers, manufacturers, recyclers, and brands across various industries, including chemicals, plastics, and metals, in tracing materials and sharing their environmental footprint securely. Its primary offering, the digital product passport, compiles detailed records of a product's origin, material composition, and environmental data, supported by a blockchain-powered chain of custody for data security. Circularise's platform enables companies to assess their Scope 3 emissions and comply with regulatory requirements related to sustainability. Furthermore, it offers tools for conducting Life Cycle Assessments and calculating Product Carbon Footprints, ensuring a reliable record of environmental impact. The MassBalancer solution helps manage materials while adhering to defined processes, enabling efficient generation of sustainability declarations. Central to Circularise’s approach is the patented Smart Questioning feature, which empowers clients to control their data sharing, thereby enhancing privacy and minimizing manual errors in reporting sourcing, carbon footprint, and human rights issues.

JustLight is a medical device company focused on developing innovative light-based technologies for health and wellness. The company's flagship product utilizes precise light wavelengths to treat joint and muscle pain while also addressing issues related to disinfection and pathogen elimination. JustLight’s technology employs photochemistry and biomechanics to effectively sterilize harmful germs and viruses on the skin's surface using skin-safe germicidal light. With a patent-pending system, the device automatically adjusts its LED light output to replicate clinical treatment parameters, delivering targeted photobiomodulation therapy. This approach allows individuals to experience effective pain relief and sanitization in the comfort of their own homes, all without the need for water, chemicals, or associated waste.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

OriCiro Genomics is a Japanese biotechnology company founded in 2018, based in Minato-ku. It specializes in developing innovative genome technologies, particularly focusing on cell-free synthesis and amplification of large DNA molecules for synthetic biology applications. The company's core technologies include DNA assembly and circular DNA amplification, which enable the construction of large circular DNA molecules without traditional biological cloning methods. OriCiro Genomics serves life science research and development companies, offering solutions that facilitate advancements in gene therapy, pharmaceuticals, diagnostics, food, and agriculture by leveraging synthetic biology.

Bionova Scientific, Inc. is a biologics contract development and manufacturing organization (CDMO) based in Fremont, California. Founded by a team of biopharmaceutical specialists in 2014, the company specializes in providing comprehensive services for biologics development and manufacturing. Bionova offers expertise in cell line development for new biological entities and biosimilars, as well as early-stage research material generation and process development. The company focuses on protein production from mammalian cell cultures, optimizing expression systems, adapting hosts, selecting media, and developing cell culture processes for scale-up. Bionova supports the bioproduction of various biomolecules, including glycoproteins, monoclonal antibodies (Mabs), Fab fragments, enzymes, Fc-fusions, and bi-specifics. Through its contract manufacturing services, Bionova Scientific aims to facilitate and expedite the development of biologic therapies for its clients.

Bionique Testing Laboratories, Inc. specializes in mycoplasma testing and consultation services tailored to the specific scientific and regulatory requirements of its clients. The company is committed to delivering high-quality mycoplasma testing products and services that adhere to individual quality standards, ensuring that clients in the life sciences sector can effectively advance their projects from concept through clinical trials to commercialization. Bionique Testing Laboratories is recognized as a global leader in mycoplasma testing, providing final drug product release testing in compliance with regulatory guidelines, utilizing a good manufacturing practices compliant real-time PCR assay.

Moment Energy focuses on developing sustainable battery energy storage systems that repurpose retired electric vehicle batteries. By utilizing these repurposed batteries, the company aims to enhance energy reliability for both on-grid and off-grid applications. Its solutions are designed to provide clean, reliable, and cost-effective energy storage, catering to the needs of off-grid areas and addressing peak demand in on-grid regions. Moment Energy's innovative approach allows industrial and off-grid customers to access affordable energy storage, thereby promoting the use of renewable energy sources.

HistoWiz, Inc. is a histology service company based in Brooklyn, New York, that specializes in the processing, embedding, cutting, and staining of mouse tissue specimens for cancer researchers in academia and the pharmaceutical industry. Established in 2012, HistoWiz operates a fully automated histology laboratory and utilizes an innovative online pathologist network. The company processes and annotates tissue samples, which are then stored in its cloud-based database, PathologyMap. This platform serves as a valuable resource for researchers, facilitating efficient information exchange and enabling the integration of technology in digital pathology. By automating histopathology processes, HistoWiz aims to provide rapid turnaround times and support the advancement of cancer research through enhanced data management and experimental expertise.

Plant Prefab specializes in constructing custom single-family and multi-family homes using advanced prefabrication methods. Their proprietary Plant Building System employs digital modeling and modular components called Plant Panels and Plant Modules, allowing contractors and developers to complete projects 20-50% faster than traditional on-site construction. This system ensures superior quality control, design flexibility, and significant time, cost, and material efficiency. Committed to sustainability, Plant Prefab aims to build a better world by design, having achieved carbon-neutral operations since 2020 and being the first housing prefabricator to announce a net-zero goal.

Curreio is a biotechnology company that develops a platform for drug discovery using structural analysis with cryo-electron microscopy. The platform enables observation of in vivo structures by freezing samples without staining, supporting the discovery and analysis of life-saving drugs through structural analysis–based approaches.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Super Home Inc. offers a subscription-based service designed to assist homeowners with care and repair for their properties. Founded in 2014 and headquartered in San Francisco, California, the company serves members in Washington, DC, and Maryland. Super provides coverage for repairs and replacements of appliances and home systems that experience breakdowns. Users can conveniently access services through various devices, including desktop and mobile platforms. Additionally, Super's maintenance schedule helps homeowners understand their property's needs, ensuring they receive timely assistance without incurring high costs.

SolidBlock Ltd is a company that offers a comprehensive platform designed for real estate developers and fund managers to facilitate fundraising through digital securities. Founded in 2018 and headquartered in Jerusalem, Israel, SolidBlock focuses on the intersection of finance and real estate, providing innovative solutions in tokenization and fintech. The platform enables users to efficiently connect with investors, streamlining the process of raising capital for various real estate projects.

PeptiStar Inc. is a technology-driven company based in Osaka, Japan, specializing in the manufacturing of peptide medicines. Founded in 2017, PeptiStar operates as a Contract Development and Manufacturing Organization (CDMO), focusing on the production of peptide active pharmaceutical ingredients (APIs). The company offers a range of peptide types, including traditional, constrained, macrocyclic, and stapled peptides that incorporate non-natural amino acids. By leveraging innovative manufacturing technologies, PeptiStar provides high value-added services to its clients, aiming to accelerate the development of peptide therapeutics and enhance the overall pharmaceutical industry. The company is committed to promoting open innovation, introducing advanced synthetic methods that facilitate the creation of effective peptide medicines.

Everactive, Inc., based in Santa Clara, California, specializes in developing wireless sensing devices and technologies for Industrial IoT analytics. Founded in 2012 and formerly known as PsiKick, the company offers custom ultra-low-power chips that enable battery-less wireless sensors, forming the backbone of its end-to-end IoT data services. Everactive's innovative circuit design and wireless communication capabilities allow for intelligent instrumentation of industrial operations, providing solutions such as steam trap monitoring, flare system monitoring, and machine health monitoring. The company's technology focuses on enabling low-cost, long-lived devices powered exclusively by harvested energy, allowing for continuous data analysis across a wide range of applications. In addition to its headquarters, Everactive has locations in Charlottesville, Virginia, and Ann Arbor, Michigan.

Aryballe Technologies, established in 2014 and based in Grenoble, France, specializes in developing innovative sensors and software that mimic the human sense of smell. The company's core products include eNose, O-Cell, NeOse Pro, and Solgel, which use biochemistry, optics, and machine learning to identify, measure, and represent odors. Aryballe's solutions are designed to enhance decision-making in various industries such as food and beverage, cosmetics, and automotive, by aiding in research and development, quality control, manufacturing, and end-user experiences.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

UltraSense Systems develops integrated 3D ultrasound sensor solutions for various industries. The company's flagship product, TouchPoint sensors, provides a low-power user interface that can detect touch and force through virtually any material using patented 3D ultrasound technology. These sensors are utilized in applications ranging from mobile phones and wearables to home appliances, automotive, medical, and industrial sectors. UltraSense Systems was founded in 2017 and is headquartered in Santa Clara, California, with additional locations in Shanghai, China, and Zhubei City, Taiwan. The company distributes its products through various channels.

Veloxis Pharmaceuticals A/S is a specialty pharmaceutical company dedicated to improving the lives of transplant patients through the development and commercialization of targeted medications. The company focuses on Envarsus XR, a once-daily tacrolimus tablet designed to prevent organ rejection in kidney transplant recipients. Envarsus XR has demonstrated non-inferiority to the market-leading immunosuppressant, Prograf, in key clinical trials. Veloxis employs its proprietary MeltDose technology to enhance the absorption and bioavailability of orally administered drugs, which has been validated through clinical studies and is also used in the formulation of Envarsus. Founded in 2002 as a spin-off from H. Lundbeck A/S, Veloxis is headquartered in Copenhagen, Denmark, and operates a subsidiary in the United States. The company has received regulatory approvals for Envarsus XR in both the European Union and the United States, underscoring its commitment to addressing the needs of transplant patients.

AiCure, LLC is a New York-based company that specializes in developing scalable medication adherence solutions and intelligent medical assistant technologies. Utilizing a visual recognition platform, AiCure's software monitors patient progress through mobile devices, confirming medication ingestion in clinical trials and among high-risk populations. The platform employs patented facial recognition and motion-sensing technology to identify patients and medications, detect diversion, and capture evidence of adherence in real-time. This data enables immediate intervention and longitudinal tracking of adherence patterns, ultimately enhancing treatment outcomes and reducing healthcare costs. AiCure's capabilities also facilitate remote patient engagement in clinical trials by measuring digital biomarkers and monitoring patient dosing. Founded in 2010, AiCure aims to transform healthcare delivery systems through advanced data analytics and artificial intelligence.

Integral Geometry Science Inc. is a Japanese company founded in 2012, based in Kobe, that specializes in the design and development of advanced measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic fields and scattered fields, creating innovative solutions such as a microwave mammography system that effectively addresses the challenges of imaging high-density breast tissue. This technology provides clear images that aid healthcare professionals in accurately distinguishing between cancerous and non-cancerous tissue, significantly reducing the need for painful and radiation-exposing conventional screening methods. Additionally, Integral Geometry Science manufactures nondestructive inspection systems for lithium-ion batteries, further expanding its expertise in measurement systems.

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Laminate Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, founded in 2012. The company specializes in developing innovative systems to enhance vascular access for hemodialysis patients. Its flagship product, the VasQ device, is an implanted external support system designed for arteriovenous fistulas. This device is integrated during the surgical creation of the fistula and addresses critical issues such as wall tension and geometric configuration, which can lead to narrowing and blockages within the first year post-surgery. By improving the patency rates of vascular access, Laminate Medical Technologies aims to significantly reduce the failure rate of fistulas, thereby minimizing kidney-failure-related complications and the associated costs of re-interventions.

SAGE Automotive Interiors, Inc. specializes in designing, developing, and manufacturing innovative automotive interior solutions for various vehicle types, including cars, trucks, and SUVs. The company produces interior fabrics utilized in seating, headliners, door panels, and consoles, catering to the needs of automotive manufacturers globally. Established in 2009 and headquartered in Greenville, South Carolina, SAGE operates additional facilities in North America, Brazil, China, Europe, India, Japan, Korea, and Thailand. Known for its cutting-edge design and engineering capabilities, the company maintains a strong commitment to quality and service. As a subsidiary of Asahi Kasei Corporation, SAGE Automotive Interiors continues to enhance its reputation by providing advanced-performance specialty fabric materials at competitive prices, ensuring it meets the evolving demands of the automotive industry.

Atox Bio Inc. is a biotechnology company based in Ness Ziona, Israel, with an additional office in North Carolina. Founded in 2003, the company specializes in developing immunomodulators aimed at treating critically ill patients facing severe acute inflammation due to infections. Atox Bio focuses on novel modulators of the immune response, targeting both adaptive and innate pathways that play crucial roles in managing infectious and inflammatory diseases, as well as ischemia/reperfusion injuries. The company's products are designed to improve outcomes for patients suffering from rare, life-threatening infections, demonstrating significant improvements in various clinical endpoints. By enhancing the host's ability to combat infections and minimizing tissue damage during acute inflammatory events, Atox Bio aims to address serious unmet medical needs in critical care settings.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Aryballe Technologies, established in 2014 and based in Grenoble, France, specializes in developing innovative sensors and software that mimic the human sense of smell. The company's core products include eNose, O-Cell, NeOse Pro, and Solgel, which use biochemistry, optics, and machine learning to identify, measure, and represent odors. Aryballe's solutions are designed to enhance decision-making in various industries such as food and beverage, cosmetics, and automotive, by aiding in research and development, quality control, manufacturing, and end-user experiences.

Arcterus Co., Ltd. is a Japanese company founded in 2010 and headquartered in Setagaya-Ku, Japan. The company specializes in developing a digital notebook application that enables students to upload and share their class notes. Additionally, it offers an assessment tool designed for both teachers and students, enhancing the educational experience. Arcterus also operates a tutoring center, further supporting learners in their academic pursuits. The company's approach is rooted in adaptive learning principles, allowing customization of educational experiences based on individual learning styles and leveraging big data to optimize learning outcomes.

Axine Water Technologies Inc. is a Vancouver-based company specializing in innovative wastewater treatment solutions. Established in 2010, the firm focuses on developing chemical-free systems designed to address high concentrations of complex and toxic organic pollutants, including phenols, pharmaceuticals, and ammonia, in industrial wastewater. Utilizing proprietary electrolytic oxidation technology, Axine's systems effectively treat various pollutants in a single step without the need for chemicals or the production of sludge. The company's solutions cater to a diverse range of industries, including oil and gas, petrochemicals, pharmaceuticals, textiles, and waste management, helping clients reduce costs and enhance the performance of their wastewater management processes.

Mirexus Inc. is a Canadian company specializing in the development of sustainable nanoparticles for various applications, including personal care products, specialty materials, and drug delivery systems. Founded in 2008 and based in Guelph, Mirexus offers PHYTOSPHERIX, a natural biopolymer that is chemically identical to glycogen. This innovative technology, originally developed at the University of Guelph, provides significant enhancements in formulations, contributing to longer-lasting cosmetics such as moisturizers, sunscreens, and hair conditioners, as well as offerings in nutraceuticals and pharmaceuticals. Mirexus aims to create partnerships within the industry to bring its green technology to market and drive advancements in product performance across multiple sectors.

Polypore International is a developer, manufacturer, and marketer of polymer-based microporous membrane products, recognized for one of the most extensive portfolios in the industry. The company specializes in separation and filtration processes, focusing on two key segments: energy storage and separation media. In the energy storage segment, Polypore produces polypropylene and polyethylene monolayer and multilayer membrane separators for lithium batteries, which are essential components in consumer electronics such as mobile phones, laptops, and power tools. The separation media segment offers membranes and modules designed for healthcare, industrial, and specialty filtration applications, addressing the growing demand for purity and high-performance filtration solutions in various sectors. With a commitment to innovation and proven proprietary technologies, Polypore is well-positioned to capitalize on trends in mobile energy and filtration.

ZOLL Medical Corporation, a subsidiary of the Asahi Kasei Group, specializes in the development and marketing of medical devices and software solutions designed to enhance emergency care and improve the efficiency of clinical operations. The company’s product range includes defibrillators, patient monitors, CPR feedback systems, data management software, fluid resuscitation tools, and therapeutic temperature management devices. ZOLL's technologies support a wide array of users, including clinicians, emergency medical services (EMS), fire professionals, and lay rescuers, enabling them to effectively treat patients requiring resuscitation and acute critical care. By providing comprehensive solutions, ZOLL aims to advance the standards of emergency medical services and ultimately save lives.

Crystal IS is a leading manufacturer specializing in the commercialization of single-crystal aluminum nitride (AlN) substrates and ultraviolet light emitting diodes (UV LEDs) based on this technology. The company's products are designed for cost-effective and energy-efficient water and air purification applications. Crystal IS offers high-performance UVC LEDs that are suitable for a range of uses, including disinfection in consumer and commercial appliances, medical devices, and life sciences. By providing advanced solutions in water and air purification, Crystal IS enables its clients to enhance the quality and effectiveness of their products across various industries.

Envia Systems is a technology company specializing in high-performance, cost-effective energy storage solutions through the development of advanced lithium-ion batteries. The company focuses on creating batteries that deliver superior energy density by utilizing high energy electrodes, making them suitable for a range of applications, including electric vehicles and hybrid electric vehicles. Envia Systems aims to facilitate the widespread adoption of clean energy technologies by providing innovative battery solutions that combine efficiency with compact design.

Crystal IS is a leading manufacturer specializing in the commercialization of single-crystal aluminum nitride (AlN) substrates and ultraviolet light emitting diodes (UV LEDs) based on this technology. The company's products are designed for cost-effective and energy-efficient water and air purification applications. Crystal IS offers high-performance UVC LEDs that are suitable for a range of uses, including disinfection in consumer and commercial appliances, medical devices, and life sciences. By providing advanced solutions in water and air purification, Crystal IS enables its clients to enhance the quality and effectiveness of their products across various industries.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.